share_log

Tharimmune | 10-Q: Q2 2024 Earnings Report

Tharimmune | 10-Q: Q2 2024 Earnings Report

Tharimmune | 10-Q：2024財年二季報
美股SEC公告 ·  08/09 15:12

Moomoo AI 已提取核心訊息

Tharimmune, a clinical-stage biotechnology company, reported its financial performance and business developments for the quarter ended June 30, 2024. The company recorded a net loss of $2,325,057 for the quarter, with a net loss per share of $2.42. This compares to a net loss of $2,336,914 and a net loss per share of $52.06 for the same period in the previous year. The company's total operating expenses for the quarter were $2,373,454, which included research and development costs of $999,553 and general and administrative expenses of $1,373,901. Tharimmune's business development has been marked by the advancement of its therapeutic candidates, including TH104, which has shown positive results in a Phase 1 clinical trial. The company has also entered into significant agreements, such as the Avior License Agreement for the development of TH104 and TH103, and the Enkefalos License Agreement for global rights to cyclotides for delivering HER2 antibodies. Tharimmune's future plans include pursuing a 505(b)(2) approval pathway for TH104, initiating a Phase 2 trial for chronic pruritus in PBC patients, and advancing TH3215 and TH1940 into IND-enabling studies in 2025.
Tharimmune, a clinical-stage biotechnology company, reported its financial performance and business developments for the quarter ended June 30, 2024. The company recorded a net loss of $2,325,057 for the quarter, with a net loss per share of $2.42. This compares to a net loss of $2,336,914 and a net loss per share of $52.06 for the same period in the previous year. The company's total operating expenses for the quarter were $2,373,454, which included research and development costs of $999,553 and general and administrative expenses of $1,373,901. Tharimmune's business development has been marked by the advancement of its therapeutic candidates, including TH104, which has shown positive results in a Phase 1 clinical trial. The company has also entered into significant agreements, such as the Avior License Agreement for the development of TH104 and TH103, and the Enkefalos License Agreement for global rights to cyclotides for delivering HER2 antibodies. Tharimmune's future plans include pursuing a 505(b)(2) approval pathway for TH104, initiating a Phase 2 trial for chronic pruritus in PBC patients, and advancing TH3215 and TH1940 into IND-enabling studies in 2025.
臨床生物技術公司Tharimmune公佈了截至2024年6月30日的財務業績和業務發展情況。該公司本季度錄得淨虧損2325057美元，每股淨虧損2.42美元。相較於同期去年的淨虧損2336914美元和每股淨虧損52.06美元，有所好轉。本季度該公司的總營業費用爲2373454美元，其中包括999553美元的研究和開發成本和1373901美元的一般和管理費用。Tharimmune的業務發展已經取得進展，其中包括TH104在一期臨床試驗中取得了積極的結果。該公司還進入了重大協議，如Avior許可協議，用於開發TH104和TH103，以及Enkefalos 許可協議，用於全球範圍內 HER2抗體給藥的環狀肽的權利。Tharimmune的未來計劃包括追求TH104的505（b）（2）批准途徑，啓動PBC患者慢性瘙癢的二期試驗，並在2025年推進TH3215 和TH1940進入IND-enabling 研究。
臨床生物技術公司Tharimmune公佈了截至2024年6月30日的財務業績和業務發展情況。該公司本季度錄得淨虧損2325057美元，每股淨虧損2.42美元。相較於同期去年的淨虧損2336914美元和每股淨虧損52.06美元，有所好轉。本季度該公司的總營業費用爲2373454美元，其中包括999553美元的研究和開發成本和1373901美元的一般和管理費用。Tharimmune的業務發展已經取得進展，其中包括TH104在一期臨床試驗中取得了積極的結果。該公司還進入了重大協議，如Avior許可協議，用於開發TH104和TH103，以及Enkefalos 許可協議，用於全球範圍內 HER2抗體給藥的環狀肽的權利。Tharimmune的未來計劃包括追求TH104的505（b）（2）批准途徑，啓動PBC患者慢性瘙癢的二期試驗，並在2025年推進TH3215 和TH1940進入IND-enabling 研究。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間